NCT04292912View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema

PHASE1TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 7, 2020

Primary Completion Date

April 11, 2022

Study Completion Date

April 11, 2022

Conditions
Macular Edema
Interventions
DRUG

GSK2798745

GSK2798745 will be administered.

Trial Locations (11)

2145

GSK Investigational Site, Westmead

2154

GSK Investigational Site, Castle Hill

3004

GSK Investigational Site, Melbourne

5000

GSK Investigational Site, Adelaide

8011

GSK Investigational Site, Christchurch

11967

GSK Investigational Site, Shirley

33467

GSK Investigational Site, Lake Worth

33880

GSK Investigational Site, Winter Haven

45202

GSK Investigational Site, Cincinnati

78503

GSK Investigational Site, McAllen

95841

GSK Investigational Site, Sacramento

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT04292912 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema | Biotech Hunter | Biotech Hunter